Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

The Biotech Industry’s Relationship with Real-Time Data: Q&A with Dr. Richard Graham

Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report

Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?

Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi

Pharmaceutical Executive: April 2026 Interactive Digital Edition

Articles in this issue

Trending on PharmExec

The Biotech Industry’s Relationship with Real-Time Data: Q&A with Dr. Richard Graham

Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report

Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?

Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi

The Evolving Relationship Between FDA and Biotech